Special Issue

Pharmacotherapy of Muscle Dystrophies

Message from the Guest Editor

Muscular dystrophies involve a large list of primary diseases due to mutations in more than 70 specific genes, which result in the observation of dystrophic changes in different muscles. In other words, degenerated muscle is usually replaced by fibrous tissues unable to perform normal muscle function. Importantly, in several cases, is not only the skeletal muscle affected, but also other tissues, such as the heart, eyes, spine, endocrine glands, brain, etc. Given the numerous genetic defects identified today, as well as our improved understanding of the pathogenesis of some of these diseases, novel therapeutic approaches have been developed. From the large list of muscular dystrophy diseases, only Duchenne muscular dystrophy has recently achieved approval for a few personalized therapies, with the rest of the diseases in different position through the drug development pathway. In this Special Issue, we concentrate on assembling examples of therapeutic opportunities and developments for some of the diseases into the group of muscular dystrophy conditions.

Guest Editor

Dr. Arturo López Castel

Translational Genomics Group, Biology Faculty, University of Valencia, 46100 Burjassot, Spain

Deadline for manuscript submissions

closed (30 November 2023)

Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/137355

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals

Pharmaceutical

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/pharmaceuticals

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.
We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter
Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

MDPI